Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash

Onkologie

Volumn 35, Issue 12, 2012, Pages 747-752

  Takashima, Naoki ^a   Kimura, Tomoki ^b   Watanabe, Naohiro ^b   Umemura, Takumi ^a   Katsuno, Shinya ^a   Arakawa, Keiko ^a   Fukatsu, Masahiro ^a   Nakamura, Naoto ^a   Nishiyama, Osamu ^c   Kataoka, Kensuke ^b   Kondoh, Yasuhiro ^b   Taniguchi, Hiroyuki ^b  

^a Department of Pharmacy ^*  (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dose reduction; Erlotinib; Non small cell lung cancer; Skin rash

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; RASH; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871102869     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000345039     Document Type: Article

References (15)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L: National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005;353:123-132.
2. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N: Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:1439-1445.
3. Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N: Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010;30:557-563.
4. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921.
5. Pérez-Soler R: Can rash associated with HER1/ EGFR inhibition be used as a marker of treatment outcome? Oncology 2003;17:23-28.
6. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
7. Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E: Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009;66:257-261.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
9. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME: Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-621.
10. Binder D, Buckendahl AC, Hübner RH, Schlattmann P, Temmesfeld-Wollbrück B, Beinert T, Suttorp N: Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol 2012;29: 193-198.
11. Sobin L, Wittekind C: UICC TNM Classification of Malignant Tumors, ed 6, revised. New York, Wiley-Liss, 2002.
12. Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A: Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs 2009;20:856-866.
13. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C: Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 2010;78:249-258.
14. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010;5:1048-1053.
15. Lind JS, Postmus PE, Heideman DA, Thunnissen EB, Bekers O, Smit EF: Dramatic response to lowdose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. J Thorac Oncol 2009;4:1585-1586.